fashion -WSS

fashion

author：knowledge 2025-10-04 03:59:27 - browse：52

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Takeda, Janssen join wearable maker to measure scratching

WSS

Change Healthcare payments predicted restored March 15

Disappointing trial forces Pfizer to pivot on obesity medicine plans

J&J to emphasize cancer drugs, stop much of its vaccine research

Disappointing trial forces Pfizer to pivot on obesity medicine plans

30 years of 'Listening to Prozac'

30 years of 'Listening to Prozac'

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

The drug industry has found itself all alone in Washington

23andMe had bad news about my health. I wish a person had delivered it

With psoriasis trial ahead, Alumis raises $259 million

Medical records are filled with copy

RSV shot was 90% effective at preventing hospitalizations in kids

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC marks new Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Organ aging and disease risk measured by new blood test

leisure time

The EPA's new lead rule: How one expert crunched the numbers

In his State of the Union, Biden takes clear aim at 'Big Pharma'

NEJM study link tiny plastics in blood vessels to heart problems

Takeda, Janssen join wearable maker to measure scratching

RSV shot was 90% effective at preventing hospitalizations in kids

Former medical device CEO who sold dummy, plastic parts convicted of fraud

knowledge

focus

focus

hotspot